To help illustrate the long history of DNA vaccine failure, this article will trace the history of clinical trials of genetic HIV vaccines. It’ll also take a look at the development of tests of infection in the 1980s which are being used to stage a fake pandemic in the years 2020 to 2021.
No vaccine can be deemed ‘safe’, and every vaccine is different. However, anyone looking for more information on the potential risks of the coronavirus vaccines should know that almost every aspect of them has been tested. This is important, not only because it casts light on what the coronavirus vaccines contain, but also because it shows just how much effort has gone into them. Essentially, groups like the Pox-Protein Public Private Partnership, set up by the Gates Foundation, NIH, GSK, and others, have been conducting large-scale experiments with genetic vaccines across Africa for years. This was in response to lots of ‘confirmed cases’ of Zika, Ebola, HIV, etc., and means thousands of people have now been dosed with various forms of synthetic DNA and mutant viruses designed and created in a lab.
The Pox-Protein Public-Private Partnership
Some of the biggest trials of genetic vaccines have been for HIV, which the Pox-Protein Public Private Partnership has spent the last ten years trying to get to market, without success. Known as the P5 for short, the group was set up in 2010 by the Bill & Melinda Gates Foundation, the National Institutes of Health, Sanofi Pasteur, GlaxoSmithKline (GSK), the South African Medical Research Council, the HIV Vaccine Trials Network (HVTN), and the US Military HIV Research Program. This was to continue the long-running RV144 trials of recombinant glycoprotein vaccines for HIV which date back to the early 1990s, with the development of AIDSVAX, a vaccine containing the recombinant glycoprotein gp160, which is a small molecular sequence said to be found on the surface of a HIV virus.
In 1993, gp160 was used in a phase I trial, and in 2002, trials of gp120 got to phase 3. However, throughout all the trials, the vaccines have shown only “modest protective efficacy”; namely, by failing to reduce ‘infection’ rates. Another trial was the STEP study (by Merck), which used three chimp ‘Ad5’ viruses that would get people to produce several different HIV proteins, but the study was stopped in 2007 because there were higher rates of HIV infection in the vaccinated group than in the placebo.